Gedatolisib combined with Faslodex and Ibrance improved progression-free survival in patients with advanced breast cancer ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or ...

Trial data showed the drug dramatically reduced cancer progression risk in certain patients, supporting Celcuity’s plans to ...

Celcuity shares jump as gedatolisib shows strong efficacy in HR+/HER2- breast cancer Phase 3 trial, with FDA filing expected ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

In a randomized pilot study recently published in the Journal for ImmunoTherapy of Cancer, an international research team led ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

Panelists discuss how the updated SEQUOIA Arm C data demonstrate that zanubrutinib monotherapy achieves a remarkable 72% ...

Corticosteroid use, particularly at high doses, decreases the effectiveness of ICI therapy in patients with non–small cell ...

Researchers at Sylvester Comprehensive Cancer Center reveal how body composition analysis predicts treatment response in ...

Lantern Pharma has completed targeted enrolment for its multi-centre Phase II HARMONIC clinical trial of a disulfide small ...